Eric serves as President and CEO of New Day Diagnostics, the recently merged fully-integrated Diagnostics shop combining the biomarker discovery and diagnostic CRO-services of former EDP Biotech Corporation with product development and commercialization capabilities of the former New Day Diagnostics, LLC.

New Day Diagnostics is a fully-integrated diagnostics products, CRO services, and clinical laboratory specializing in cancer, infectious disease, and digestive disease. The company’s product and service offerings include the first FDA-approved screening test ColoPlex®, a new diagnostic blood test for early detection of colorectal cancer and precancerous polyps. His passion is developing and launching novel biotechnologies onto the market in affordable and accessible modalities for all. To that end, he also sits on the Board of New Day Diagnostics, Life Science Tennessee, Tennessee BioSTEM Education Coalition, and founded the non-profit Andrew B. Mayer Foundation.